Pralatrexate (Folotyn) for Peripheral T-Cell Lymphoma
The FDA has approved pralatrexate (Folotyn – Allos), an intravenous (IV) antifolate, for treatment of adults with relapsed or refractory peripheral T-cell lymphoma (PTCL). It is the first drug approved by the FDA specifically for this indication....
Cannot Access - We are sorry, but you cannot access the requested article.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
Information about the article:
Title: Pralatrexate (Folotyn) for Peripheral T-Cell Lymphoma
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1342
Article Code: 1342c
Date: July 12, 2010
Volume: 52
Pages: 55-56
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1342
Article Code: 1342c
Date: July 12, 2010
Volume: 52
Pages: 55-56
Add this downloadable, electronic article to your cart (U.S. English version only) Subscribe to The Medical Letter on Drugs and Therapeutics for instant access to this article.